Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies.
about
Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Long-term safety of tiotropium ...... irment in the TONADO® studies.
@en
Long-term safety of tiotropium ...... irment in the TONADO® studies.
@nl
type
label
Long-term safety of tiotropium ...... irment in the TONADO® studies.
@en
Long-term safety of tiotropium ...... irment in the TONADO® studies.
@nl
altLabel
Long-term safety of tiotropium ...... pairment in the TONADO studies
@en
prefLabel
Long-term safety of tiotropium ...... irment in the TONADO® studies.
@en
Long-term safety of tiotropium ...... irment in the TONADO® studies.
@nl
P2093
P2860
P921
P356
P1476
Long-term safety of tiotropium ...... irment in the TONADO® studies.
@en
P2093
Craig LaForce
Eric Derom
Isabel M Kloer
Matthias Trampisch
Roland Buhl
Ulrich Bothner
P2860
P304
P356
10.2147/COPD.S161489
P407
P577
2018-06-01T00:00:00Z